APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease
This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. Data from the National Alzheimer's Coordinating...
Gespeichert in:
| Veröffentlicht in: | Nature medicine Jg. 30; H. 5; S. 1284 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.05.2024
|
| Schlagworte: | |
| ISSN: | 1546-170X, 1546-170X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. Data from the National Alzheimer's Coordinating Center and five large cohorts with AD biomarkers were analyzed. The analysis included 3,297 individuals for the pathological study and 10,039 for the clinical study. Findings revealed that almost all APOE4 homozygotes exhibited AD pathology and had significantly higher levels of AD biomarkers from age 55 compared to APOE3 homozygotes. By age 65, nearly all had abnormal amyloid levels in cerebrospinal fluid, and 75% had positive amyloid scans, with the prevalence of these markers increasing with age, indicating near-full penetrance of AD biology in APOE4 homozygotes. The age of symptom onset was earlier in APOE4 homozygotes at 65.1, with a narrower 95% prediction interval than APOE3 homozygotes. The predictability of symptom onset and the sequence of biomarker changes in APOE4 homozygotes mirrored those in autosomal dominant AD and Down syndrome. However, in the dementia stage, there were no differences in amyloid or tau positron emission tomography across haplotypes, despite earlier clinical and biomarker changes. The study concludes that APOE4 homozygotes represent a genetic form of AD, suggesting the need for individualized prevention strategies, clinical trials and treatments. |
|---|---|
| AbstractList | This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. Data from the National Alzheimer's Coordinating Center and five large cohorts with AD biomarkers were analyzed. The analysis included 3,297 individuals for the pathological study and 10,039 for the clinical study. Findings revealed that almost all APOE4 homozygotes exhibited AD pathology and had significantly higher levels of AD biomarkers from age 55 compared to APOE3 homozygotes. By age 65, nearly all had abnormal amyloid levels in cerebrospinal fluid, and 75% had positive amyloid scans, with the prevalence of these markers increasing with age, indicating near-full penetrance of AD biology in APOE4 homozygotes. The age of symptom onset was earlier in APOE4 homozygotes at 65.1, with a narrower 95% prediction interval than APOE3 homozygotes. The predictability of symptom onset and the sequence of biomarker changes in APOE4 homozygotes mirrored those in autosomal dominant AD and Down syndrome. However, in the dementia stage, there were no differences in amyloid or tau positron emission tomography across haplotypes, despite earlier clinical and biomarker changes. The study concludes that APOE4 homozygotes represent a genetic form of AD, suggesting the need for individualized prevention strategies, clinical trials and treatments.This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. Data from the National Alzheimer's Coordinating Center and five large cohorts with AD biomarkers were analyzed. The analysis included 3,297 individuals for the pathological study and 10,039 for the clinical study. Findings revealed that almost all APOE4 homozygotes exhibited AD pathology and had significantly higher levels of AD biomarkers from age 55 compared to APOE3 homozygotes. By age 65, nearly all had abnormal amyloid levels in cerebrospinal fluid, and 75% had positive amyloid scans, with the prevalence of these markers increasing with age, indicating near-full penetrance of AD biology in APOE4 homozygotes. The age of symptom onset was earlier in APOE4 homozygotes at 65.1, with a narrower 95% prediction interval than APOE3 homozygotes. The predictability of symptom onset and the sequence of biomarker changes in APOE4 homozygotes mirrored those in autosomal dominant AD and Down syndrome. However, in the dementia stage, there were no differences in amyloid or tau positron emission tomography across haplotypes, despite earlier clinical and biomarker changes. The study concludes that APOE4 homozygotes represent a genetic form of AD, suggesting the need for individualized prevention strategies, clinical trials and treatments. This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. Data from the National Alzheimer's Coordinating Center and five large cohorts with AD biomarkers were analyzed. The analysis included 3,297 individuals for the pathological study and 10,039 for the clinical study. Findings revealed that almost all APOE4 homozygotes exhibited AD pathology and had significantly higher levels of AD biomarkers from age 55 compared to APOE3 homozygotes. By age 65, nearly all had abnormal amyloid levels in cerebrospinal fluid, and 75% had positive amyloid scans, with the prevalence of these markers increasing with age, indicating near-full penetrance of AD biology in APOE4 homozygotes. The age of symptom onset was earlier in APOE4 homozygotes at 65.1, with a narrower 95% prediction interval than APOE3 homozygotes. The predictability of symptom onset and the sequence of biomarker changes in APOE4 homozygotes mirrored those in autosomal dominant AD and Down syndrome. However, in the dementia stage, there were no differences in amyloid or tau positron emission tomography across haplotypes, despite earlier clinical and biomarker changes. The study concludes that APOE4 homozygotes represent a genetic form of AD, suggesting the need for individualized prevention strategies, clinical trials and treatments. |
| Author | Sperling, Reisa Belbin, Olivia Vaqué-Alcázar, Lídia Alcolea, Daniel Johnson, Sterling C Fortea, Juan Gispert, Juan Domingo Bejanin, Alexandre Montal, Víctor Pegueroles, Jordi Videla, Laura Lleó, Alberto Suárez-Calvet, Marc Dols-Icardo, Oriol |
| Author_xml | – sequence: 1 givenname: Juan orcidid: 0000-0002-1340-638X surname: Fortea fullname: Fortea, Juan email: jfortea@santpau.cat, jfortea@santpau.cat, jfortea@santpau.cat organization: Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain. jfortea@santpau.cat – sequence: 2 givenname: Jordi orcidid: 0000-0002-3554-2446 surname: Pegueroles fullname: Pegueroles, Jordi organization: Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Barcelona, Spain – sequence: 3 givenname: Daniel orcidid: 0000-0002-3819-3245 surname: Alcolea fullname: Alcolea, Daniel organization: Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Barcelona, Spain – sequence: 4 givenname: Olivia orcidid: 0000-0002-6109-6371 surname: Belbin fullname: Belbin, Olivia organization: Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Barcelona, Spain – sequence: 5 givenname: Oriol orcidid: 0000-0003-2656-8748 surname: Dols-Icardo fullname: Dols-Icardo, Oriol organization: Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Barcelona, Spain – sequence: 6 givenname: Lídia surname: Vaqué-Alcázar fullname: Vaqué-Alcázar, Lídia organization: Department of Medicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain – sequence: 7 givenname: Laura orcidid: 0000-0002-9748-8465 surname: Videla fullname: Videla, Laura organization: Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain – sequence: 8 givenname: Juan Domingo surname: Gispert fullname: Gispert, Juan Domingo organization: Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain – sequence: 9 givenname: Marc orcidid: 0000-0002-2993-569X surname: Suárez-Calvet fullname: Suárez-Calvet, Marc organization: Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain – sequence: 10 givenname: Sterling C orcidid: 0000-0002-8501-545X surname: Johnson fullname: Johnson, Sterling C organization: Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA – sequence: 11 givenname: Reisa orcidid: 0000-0003-1535-6133 surname: Sperling fullname: Sperling, Reisa organization: Brigham and Women's Hospital Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA – sequence: 12 givenname: Alexandre orcidid: 0000-0002-9958-0951 surname: Bejanin fullname: Bejanin, Alexandre organization: Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Barcelona, Spain – sequence: 13 givenname: Alberto orcidid: 0000-0002-2568-5478 surname: Lleó fullname: Lleó, Alberto organization: Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Barcelona, Spain – sequence: 14 givenname: Víctor orcidid: 0000-0002-5714-9282 surname: Montal fullname: Montal, Víctor email: victor.montal@protonmail.com, victor.montal@protonmail.com, victor.montal@protonmail.com organization: Barcelona Supercomputing Center, Barcelona, Spain. victor.montal@protonmail.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38710950$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LAzEYhINUrK3-AQ-Sm15Wk0022RxLqR9QqAcFb0s2-6aN7G7WJEXaX2_FCh6GmcPDwMwEjXrfA0JXlNxRwsr7yGmhaEZyfpBiNPs6Qee04CKjkryP_uUxmsT4QQhhpFBnaMxKSYkqyDlazl5WC443vvP73drvXdrhAEOACH2KWOPGxeR6k_AaekjOYOtDh73Fs3a_AddBuIk_EOgIF-jU6jbC5dGn6O1h8Tp_yparx-f5bJkNOaUpE7KsiQTb2FJb4KLONQhpCklFYwBKYZpa2loxroRVhpecaklBk7xWTaGATdHtb-8Q_OcWYqo6Fw20re7Bb2N1WEkVk5zLA3p9RLd1B001BNfpsKv-HmDfF7lg1Q |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. |
| Copyright_xml | – notice: 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1038/s41591-024-02931-w |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1546-170X |
| ExternalDocumentID | 38710950 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) grantid: PI20/01330 – fundername: EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) grantid: H2020-SC1-BHC-2018-2020 – fundername: U.S. Department of Health & Human Services | National Institutes of Health (NIH) grantid: R21AG056974 – fundername: U.S. Department of Health & Human Services | National Institutes of Health (NIH) grantid: R01 AG027161, R01 AG037639, R01 AG054059; UF1AG051216, P50 AG033514, and P30 AG062715 – fundername: EC | EU Framework Programme for Research and Innovation H2020 | H2020 The European Institute of Innovation and Technology | EIT Digital (EIT Digital IVZW) grantid: Grant 2021 – fundername: Alzheimer's Association grantid: AARG-22-923680 – fundername: Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) grantid: PI22/00456 – fundername: EC | EU Framework Programme for Research and Innovation H2020 | H2020 European Institute of Innovation and Technology (H2020 The European Institute of Innovation and Technology) grantid: 948677 and 847648 – fundername: Generalitat de Catalunya (Government of Catalonia) grantid: SLT002/16/00408 – fundername: Generalitat de Catalunya (Government of Catalonia) grantid: SLT006/17/00119 |
| GroupedDBID | --- .-4 .55 .GJ 0R~ 123 1CY 29M 2FS 36B 39C 3O- 4.4 53G 5M7 5RE 5S5 70F 7X7 85S 88E 88I 8AO 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AARCD AAYZH ABAWZ ABCQX ABDBF ABDPE ABEFU ABFSG ABJNI ABLJU ABOCM ABUWG ACBWK ACGFO ACGFS ACGOD ACIWK ACMJI ACPRK ACSTC ACUHS ADBBV ADFRT AENEX AETEA AEUYN AEZWR AFANA AFBBN AFHIU AFKRA AFRAH AFSHS AGAYW AGCDD AHBCP AHMBA AHOSX AHSBF AHWEU AIBTJ AIXLP ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS ALPWD AMTXH ARMCB ASPBG ATHPR AVWKF AXYYD AZFZN AZQEC B0M BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CCPQU CGR CS3 CUY CVF DB5 DU5 DWQXO EAD EAP EBC EBD EBS ECM EE. EIF EJD EMB EMK EMOBN EPL ESX EXGXG F5P FEDTE FQGFK FSGXE FYUFA GNUQQ GUQSH HCIFZ HMCUK HVGLF HZ~ IAO IEA IH2 IHR IHW INH INR IOF IOV ISR ITC J5H L7B LGEZI LK8 LOTEE M1P M2O M2P M7P MK0 N9A NADUK NFIDA NNMJJ NPM NXXTH O9- ODYON P2P PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO Q2X RIG RNS RNT RNTTT RVV SHXYY SIXXV SJN SNYQT SOJ SV3 TAE TAOOD TBHMF TDRGL TSG TUS UKHRP UQL X7M XJT YHZ ZGI ~8M 7X8 AGSTI PUEGO |
| ID | FETCH-LOGICAL-p211t-678b07efdf8afe46b2ae67c5716dcee86cdb7fb93496f9c4841a71ea02b9d59e3 |
| ISICitedReferencesCount | 193 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001214916900002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1546-170X |
| IngestDate | Thu Oct 02 16:36:13 EDT 2025 Mon Jul 21 06:00:29 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-p211t-678b07efdf8afe46b2ae67c5716dcee86cdb7fb93496f9c4841a71ea02b9d59e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-8501-545X 0000-0002-2568-5478 0000-0002-6109-6371 0000-0002-9748-8465 0000-0002-3819-3245 0000-0002-2993-569X 0000-0003-1535-6133 0000-0002-9958-0951 0000-0003-2656-8748 0000-0002-1340-638X 0000-0002-3554-2446 0000-0002-5714-9282 |
| PMID | 38710950 |
| PQID | 3051937447 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3051937447 pubmed_primary_38710950 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-01 |
| PublicationDateYYYYMMDD | 2024-05-01 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Nature medicine |
| PublicationTitleAlternate | Nat Med |
| PublicationYear | 2024 |
| References | 38886628 - Nat Med. 2024 Jul;30(7):2093. doi: 10.1038/s41591-024-03127-y. 38831096 - Nat Rev Neurol. 2024 Jul;20(7):379. doi: 10.1038/s41582-024-00985-5. |
| References_xml | – reference: 38831096 - Nat Rev Neurol. 2024 Jul;20(7):379. doi: 10.1038/s41582-024-00985-5. – reference: 38886628 - Nat Med. 2024 Jul;30(7):2093. doi: 10.1038/s41591-024-03127-y. |
| SSID | ssj0003059 |
| Score | 2.7195377 |
| Snippet | This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1284 |
| SubjectTerms | Age of Onset Aged Aged, 80 and over Alzheimer Disease - cerebrospinal fluid Alzheimer Disease - diagnostic imaging Alzheimer Disease - genetics Alzheimer Disease - pathology Amyloid - genetics Amyloid - metabolism Amyloid beta-Peptides - cerebrospinal fluid Amyloid beta-Peptides - genetics Amyloid beta-Peptides - metabolism Apolipoprotein E3 - genetics Apolipoprotein E4 - genetics Biomarkers - cerebrospinal fluid Cohort Studies Female Homozygote Humans Male Middle Aged Positron-Emission Tomography tau Proteins - cerebrospinal fluid tau Proteins - genetics |
| Title | APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38710950 https://www.proquest.com/docview/3051937447 |
| Volume | 30 |
| WOSCitedRecordID | wos001214916900002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1546-170X dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0003059 issn: 1546-170X databaseCode: M7P dateStart: 20200101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1546-170X dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0003059 issn: 1546-170X databaseCode: 7X7 dateStart: 20200101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1546-170X dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0003059 issn: 1546-170X databaseCode: BENPR dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Research Library customDbUrl: eissn: 1546-170X dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0003059 issn: 1546-170X databaseCode: M2O dateStart: 20200101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1546-170X dateEnd: 20241209 omitProxy: false ssIdentifier: ssj0003059 issn: 1546-170X databaseCode: M2P dateStart: 20200101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZoC4gLgvIqj5WREBxQ1Dyc2DkWtBWHbTZCWym3yHHsNtKSLE22tPvrGTve7KIWqRy4jCJLiaPMl_GMP88MQh-k0BVhwHPzOHUdwpXnFJFPHa8UPJJhoAphEoUnNElYlsWpZUxb006A1jW7uooX_1XVMAbK1qmz_6Du4aEwANegdJCgdpB3UvxROh2Tz-fNj2Z1fdastJdtKle2JpeNa0qmq2rR6ebJOoPR5C8ah3S-OpeV6aZC2z-YG-u8JqYI6A06HmDS53dsgJbKs6XUBxctywAoHJA1B-j1d_Tp7cOGgJwXfUGD6by6rPj2foRPNqf_1iaURI5H3axfYW4Zs3bX8jHVNrNtjKheMm-17n0t9xZ8Dn1cS08Nzorn_NqsZWv-Ppnmx6eTST4bZ7OPi5-O7jKm2XjbcmUH7fk0jLUVPPGnw8oNti829XXt29okK5j28Oakfw9JjGsye4Ie25gCH_VYeIruyXofPei7jF7vo4cnVmHP0MSAA2-DA2_AgTlegwNbcGANDtwoPIDjU4stNJ6j0-Px7Os3x_bTcBYQ5ncO-CWFS6UqFeNKkqjwuYyoCCFkLsFXYpEoC6qKWPcQULEgjMAP7Enu-kVchrEMXqDduqnlK4RZ4SkYJQF1BYk4YZ4QLlFK-TJgxFUH6P364-RgrzQJxWvZLNs8MDEDJYQeoJf9V8sXfWGVPGD6ZHDovr7D3W_Qow363qLd7mIp36H74rKr2osR2qEZNZKN0N6XcZJ-HxldG5lqSdPf_KRv_Q |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=APOE4+homozygozity+represents+a+distinct+genetic+form+of+Alzheimer%27s+disease&rft.jtitle=Nature+medicine&rft.au=tea%2C+Juan&rft.au=Pegueroles%2C+Jordi&rft.au=Alcolea%2C+Daniel&rft.au=Belbin%2C+Olivia&rft.date=2024-05-01&rft.issn=1546-170X&rft.eissn=1546-170X&rft.volume=30&rft.issue=5&rft.spage=1284&rft_id=info:doi/10.1038%2Fs41591-024-02931-w&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1546-170X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1546-170X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1546-170X&client=summon |